Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Finished Goods (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 11 years of Finished Goods data on record, last reported at $37.7 million in Q3 2025.

  • For Q3 2025, Finished Goods rose 11.7% year-over-year to $37.7 million; the TTM value through Sep 2025 reached $37.7 million, up 11.7%, while the annual FY2024 figure was $39.4 million, 58.14% up from the prior year.
  • Finished Goods reached $37.7 million in Q3 2025 per AMPH's latest filing, down from $41.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $41.6 million in Q2 2025 and bottomed at $14.5 million in Q1 2022.
  • Average Finished Goods over 5 years is $25.9 million, with a median of $24.9 million recorded in 2023.
  • Peak YoY movement for Finished Goods: fell 22.62% in 2022, then skyrocketed 91.35% in 2023.
  • A 5-year view of Finished Goods shows it stood at $17.7 million in 2021, then grew by 6.97% to $18.9 million in 2022, then skyrocketed by 31.99% to $24.9 million in 2023, then surged by 58.14% to $39.4 million in 2024, then dropped by 4.34% to $37.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $37.7 million in Q3 2025, $41.6 million in Q2 2025, and $38.4 million in Q1 2025.